Liminatus Pharma, Inc.
LIMN
$1.28
-$0.03-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 473.14% | -- | 255.32% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 22.99% | -99.98% | -78.08% | ||
| Operating Income | -22.99% | 99.98% | 78.08% | ||
| Income Before Tax | 111.79% | 99.98% | 70.30% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 111.79% | 99.98% | 70.30% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 111.79% | 99.98% | 70.30% | ||
| EBIT | -22.99% | 99.98% | 78.08% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 108.93% | 100.00% | 71.01% | ||
| Normalized Basic EPS | 0.58% | 100.00% | 69.77% | ||
| EPS Diluted | 108.93% | 100.00% | 71.01% | ||
| Normalized Diluted EPS | 0.58% | 100.00% | 69.77% | ||
| Average Basic Shares Outstanding | 33.15% | 48.65% | -0.10% | ||
| Average Diluted Shares Outstanding | 33.15% | 48.65% | -0.10% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||